CS Diagnostics Corp. (CSDX)
OTCMKTS · Delayed Price · Currency is USD
0.2250
-0.0240 (-9.64%)
Jan 20, 2026, 3:07 PM EST
CS Diagnostics Revenue
CS Diagnostics had revenue of $23.05K in the quarter ending September 30, 2025, a decrease of -48.96%. This brings the company's revenue in the last twelve months to $98.73K, down -21.67% year-over-year. In the year 2024, CS Diagnostics had annual revenue of $110.91K, down -12.00%.
Revenue (ttm)
98.73K
Revenue Growth
-21.67%
P/S Ratio
569.72
Revenue / Employee
98.73K
Employees
1
Market Cap
56.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110.91K | -15.13K | -12.00% |
| Dec 31, 2023 | 126.04K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 766.00 | -109.00 | -12.46% |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2002 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
CS Diagnostics News
- 2 months ago - CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting - Accesswire
- 3 months ago - CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering - Accesswire
- 4 months ago - CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth - Accesswire
- 4 months ago - CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market - Accesswire
- 6 months ago - CS Diagnostics Corp. Submitted Final Form-10 Registration Statement Draft to the processing team for preparation of Edgardization and filing with the U.S. Securities and Exchange Commission ("SEC") - Accesswire
- 7 months ago - CS Diagnostics Corp. to Present at the Small Cap Growth Virtual Investor Conference June 26th - GlobeNewsWire
- 7 months ago - CS Diagnostics Corp. CSDX to Present at the Small Cap Growth Virtual Investor Conference on June 26, 2025 at 12:30pm EDT - Accesswire
- 10 months ago - CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS - Accesswire